• Facebook
  • Twitter
Cancer World Archive
  • Magazine
HomeDrug WatchRNA-bound: the future of antisense drugs

RNA-bound: the future of antisense drugs

Keith McCullagh

1 July 2006 Drug Watch 0

Number 13

Download pdf article

The use of nucleic acid therapies to block RNA function was first described in 1978. The latest generation of these compounds, LNA antagonists, is now overcoming the main obstacle to the success of its predecessors, through a greater ability to bind to RNA.

Download full article

  • LNA antagonists
  • RNA
Previous article
Next article

LATEST PRINTED ISSUE

Latest news

  • Four steps to eliminating HPV infections across Europe: an ECCO call for EU action

    News 16 October 2020 0
    A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating human papillomavirus (HPV) in Europe. The report was published by The European [more]

Facebook

Twitter

Tweet di @CancerworldESO

© Copyright OncoDaily 2018 with all rights reserved - Credits -


Privacy Policy Cookie Policy